1. Home
  2. KLRS vs DUOT Comparison

KLRS vs DUOT Comparison

Compare KLRS & DUOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLRS
  • DUOT
  • Stock Information
  • Founded
  • KLRS 2019
  • DUOT 1990
  • Country
  • KLRS United States
  • DUOT United States
  • Employees
  • KLRS N/A
  • DUOT N/A
  • Industry
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • DUOT Computer Software: Prepackaged Software
  • Sector
  • KLRS Health Care
  • DUOT Technology
  • Exchange
  • KLRS Nasdaq
  • DUOT Nasdaq
  • Market Cap
  • KLRS 129.0M
  • DUOT 66.3M
  • IPO Year
  • KLRS N/A
  • DUOT N/A
  • Fundamental
  • Price
  • KLRS $3.89
  • DUOT $7.05
  • Analyst Decision
  • KLRS Buy
  • DUOT Strong Buy
  • Analyst Count
  • KLRS 1
  • DUOT 2
  • Target Price
  • KLRS N/A
  • DUOT $11.50
  • AVG Volume (30 Days)
  • KLRS 62.9K
  • DUOT 117.1K
  • Earning Date
  • KLRS 05-19-2025
  • DUOT 05-15-2025
  • Dividend Yield
  • KLRS N/A
  • DUOT N/A
  • EPS Growth
  • KLRS N/A
  • DUOT N/A
  • EPS
  • KLRS N/A
  • DUOT N/A
  • Revenue
  • KLRS N/A
  • DUOT $7,280,885.00
  • Revenue This Year
  • KLRS N/A
  • DUOT $240.43
  • Revenue Next Year
  • KLRS N/A
  • DUOT $89.30
  • P/E Ratio
  • KLRS N/A
  • DUOT N/A
  • Revenue Growth
  • KLRS N/A
  • DUOT N/A
  • 52 Week Low
  • KLRS $4.19
  • DUOT $2.03
  • 52 Week High
  • KLRS $24.15
  • DUOT $8.53
  • Technical
  • Relative Strength Index (RSI)
  • KLRS N/A
  • DUOT 63.74
  • Support Level
  • KLRS N/A
  • DUOT $6.35
  • Resistance Level
  • KLRS N/A
  • DUOT $7.30
  • Average True Range (ATR)
  • KLRS 0.00
  • DUOT 0.61
  • MACD
  • KLRS 0.00
  • DUOT 0.08
  • Stochastic Oscillator
  • KLRS 0.00
  • DUOT 72.06

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.

About DUOT Duos Technologies Group Inc.

Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains while they are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.

Share on Social Networks: